Designation based on clinical research in advanced relapsed or refractory multiple myeloma Piscataway, NJ, April 3, 2019 – Legend Biotech today announced that the European Medicines Agency has granted a PRIME (PRIority MEdicines) designation to Janssen-Cilag International N.V. (Janssen) for JNJ-68284528 (JNJ-4528), the company’s investigational B cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) […]

National Academy of Sciences publishes update from three LEGEND-2 study sitesResults support findings from fourth study site previously presented at ASH 2018 Piscataway, NJ, April 15, 2019 – New data from three sites involved in the LEGEND-2 Phase 1/2 open-label study showed that treatment with the investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell […]

Legend announces that second and third milestones relating to the US clinical trial have been achieved. Piscataway, NJ, July 29, 2019 ‐ Legend Biotech is pleased to announce that, according to the terms and conditions of an Agreement with Janssen Biotech, Inc. (Janssen), the second and third milestones relating to the clinical trial in the […]

CARTITUDE-1 (MMY2001, NCT03548207), United States(US) Initial Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528*, a CAR-T Cell Therapy Directed Against BCMA, in Patients with RRMM (Abstract #577) Initial Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in RRMM, Indicates Preferential Expansion of CD8+ T Cell Central Memory […]

Designation based on the ongoing U.S. Phase 1b/2 CARTITIUDE-1 (MMY2001, NCT03548207) study in advanced relapsed or refractory multiple myeloma PISCATAWAY, NJ, DECEMBER 6, 2019 – Legend Biotech USA Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to Janssen Research & Development, LLC (Janssen) for JNJ-68284528 (JNJ-4528), […]